In these small subgroups, there was no evidence of a difference in PFS (eFigure 2 in Supplement 2) or OS (eFigure 3 in Supplement 2) for patients with tumors that harbored MMR deficiency, ARID1A loss, aberrant expression of p53, or expressed PD-1, PD-L1 or a combination of PD-1/PD-L1 in this study. This evidence concerns the gene TP53 and mismatch repair cancer syndrome 1.